Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001609251-17-000002
Filing Date
2017-02-14
Accepted
2017-02-14 15:10:54
Documents
1

Document Format Files

Seq Description Document Type Size
1 KRENSABACE ASSET MGT AVIR FORM 13G 12.31.2016 AVIR_13G_02.10.17_Amend_1.txt SC 13G 15551
  Complete submission text file 0001609251-17-000002.txt   17392
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13G | Act: 34 | File No.: 005-31596 | Film No.: 17607694
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 130 EAST 59TH STREET 11TH FLOOR NEW YORK NY 10022
Business Address 130 EAST 59TH STREET 11TH FLOOR NEW YORK NY 10022 212-888-1582
Krensavage Asset Management, LLC (Filed by) CIK: 0001609251 (see all company filings)

EIN.: 262520930 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G